[go: up one dir, main page]

NO20090619L - Aminoalkohol-derivatat og immunosuppressiv agent har det samme som en aktive ingrediens - Google Patents

Aminoalkohol-derivatat og immunosuppressiv agent har det samme som en aktive ingrediens

Info

Publication number
NO20090619L
NO20090619L NO20090619A NO20090619A NO20090619L NO 20090619 L NO20090619 L NO 20090619L NO 20090619 A NO20090619 A NO 20090619A NO 20090619 A NO20090619 A NO 20090619A NO 20090619 L NO20090619 L NO 20090619L
Authority
NO
Norway
Prior art keywords
amino alcohol
alcohol derivative
same
active ingredient
immunosuppressive agent
Prior art date
Application number
NO20090619A
Other languages
English (en)
Inventor
Yasushi Kohno
Kiyoshi Fujii
Tatsuhiro Saito
Kazuhiko Kuriyama
Tokutarou Yasue
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of NO20090619L publication Critical patent/NO20090619L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Tilveiebringelse av et aminoalkoholderivat anvendelige som et utmerket immunosuppressivt middel. Som et resultat av intensive forskning for å skape en meget sikker forbindelse som har en utmerket immunosuppressiv aktivitet ble det oppdaget at et aminoalkoholderivat representert ved den generelle formel (1), har utmerket immunosuppressiv aktivitet.
NO20090619A 2006-08-08 2009-02-10 Aminoalkohol-derivatat og immunosuppressiv agent har det samme som en aktive ingrediens NO20090619L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006215281 2006-08-08
PCT/JP2007/065426 WO2008018447A1 (en) 2006-08-08 2007-08-07 Aminoalcohol derivative and immunosuppressant containing the same as active ingredient

Publications (1)

Publication Number Publication Date
NO20090619L true NO20090619L (no) 2009-02-27

Family

ID=39032977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090619A NO20090619L (no) 2006-08-08 2009-02-10 Aminoalkohol-derivatat og immunosuppressiv agent har det samme som en aktive ingrediens

Country Status (21)

Country Link
US (1) US8273748B2 (no)
EP (1) EP2053038B1 (no)
JP (1) JP5140593B2 (no)
KR (1) KR20090041424A (no)
CN (1) CN101506145B (no)
AU (1) AU2007282556B2 (no)
CA (1) CA2659599C (no)
CO (1) CO6160222A2 (no)
GT (1) GT200900024A (no)
IL (1) IL196274A (no)
MA (1) MA30664B1 (no)
MX (1) MX2009001457A (no)
MY (1) MY146775A (no)
NO (1) NO20090619L (no)
NZ (1) NZ574012A (no)
RU (1) RU2458044C2 (no)
SG (1) SG174029A1 (no)
TN (1) TNSN08546A1 (no)
TW (1) TWI396677B (no)
WO (1) WO2008018447A1 (no)
ZA (1) ZA200900207B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5198293B2 (ja) * 2007-02-13 2013-05-15 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
EP2292594A4 (en) * 2008-05-19 2014-10-15 Kyorin Seiyaku Kk METHOD FOR PRODUCING AN OPTICALLY ACTIVE AMINO ALCOHOL DERIVATIVE
CN102123735A (zh) * 2008-05-20 2011-07-13 杏林制药株式会社 诱导缓解维持剂
PE20100371A1 (es) * 2008-10-31 2010-06-01 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de malaria cerebral

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
RU2198162C2 (ru) * 1997-04-04 2003-02-10 Мицубиси Фарма Корпорейшн Производное 2-аминопропан-1,3-диола, его фармацевтическое применение и промежуточные продукты для их синтеза
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
CA2336412C (en) * 1998-07-02 2007-11-27 Junichi Shimada Medicament for treatment of diabetes
AU767241B2 (en) * 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
WO2001098301A1 (en) 2000-06-20 2001-12-27 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
BR0112484A (pt) 2000-07-13 2003-09-23 Sankyo Co Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo
JP2002167382A (ja) 2000-07-13 2002-06-11 Sankyo Co Ltd アミノアルコ−ル誘導体
JP2002053575A (ja) 2000-08-09 2002-02-19 Sankyo Co Ltd アミノアルコ−ル類
JP2002053572A (ja) 2000-08-09 2002-02-19 Tosoh Corp 光学活性ピラン類縁体の製造方法
AU8533101A (en) * 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
AU2002237988B2 (en) * 2001-01-30 2008-01-03 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
ATE447970T1 (de) * 2001-02-08 2009-11-15 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
CA2435739A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
WO2002076995A2 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
EP1391199B1 (en) * 2001-05-10 2008-12-10 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP2004534772A (ja) * 2001-05-24 2004-11-18 藤沢薬品工業株式会社 アミノアルコール誘導体
WO2003020313A1 (en) * 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
JP2005112721A (ja) 2001-11-06 2005-04-28 Maruha Corp 含窒素化合物、製造法、及びその利用方法
WO2003051876A1 (en) 2001-12-14 2003-06-26 Japan Tobacco Inc. Pyrazolopyridine derivatives and medicinal use thereof
JP4771511B2 (ja) 2003-07-08 2011-09-14 第一三共株式会社 アミノアルコ−ル誘導体又はホスホン酸誘導体を含有する医薬組成物
DE60328161D1 (de) * 2002-01-11 2009-08-13 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
JP2003267936A (ja) 2002-01-11 2003-09-25 Sankyo Co Ltd ベンゼン環化合物
JP4709488B2 (ja) * 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
CA2477423A1 (en) * 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
AU2003218056A1 (en) * 2002-03-01 2003-09-16 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
TW200410688A (en) 2002-06-26 2004-07-01 Ono Pharmaceutical Co Therapeutics for diseases from vasoconstriction or vasodilatation
EP1546110A4 (en) 2002-07-30 2008-03-26 Univ Virginia COMPOUNDS WITH EFFECT ON SIGNAL TRANSMISSION BY SPHINGOSINE-1-PHOSPHATE
JP4166218B2 (ja) * 2002-09-13 2008-10-15 ノバルティス アクチエンゲゼルシャフト アミノ−プロパノール誘導体
US7482491B2 (en) * 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
CN1708293A (zh) * 2002-09-24 2005-12-14 诺瓦提斯公司 治疗脱髓鞘疾病的鞘氨醇－1－磷酸受体激动剂
US7820682B2 (en) * 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
JP4140698B2 (ja) 2002-10-18 2008-08-27 第一三共株式会社 リン酸又はホスホン酸誘導体
EP1581509B1 (en) * 2002-12-20 2011-01-19 Merck Sharp & Dohme Corp. 1-(amino)indanes as edg receptor agonists
MXPA05008531A (es) 2003-02-11 2005-11-17 Irm Llc Compuestos biciclicos novedosos y composiciones.
WO2004074297A1 (ja) 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
JP2004307441A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ベンゼン誘導体とその付加塩及び免疫抑制剤
JP2004307440A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
JP2004307442A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ヘテロ環誘導体とその付加塩及び免疫抑制剤
JP2004307439A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd アミノジオール誘導体とその付加塩及び免疫抑制剤
CN1777575B (zh) 2003-04-30 2010-05-12 诺瓦提斯公司 作为1-磷酸-鞘氨醇受体调节剂的氨基-丙醇衍生物
EP1622866B1 (en) 2003-04-30 2012-07-25 Novartis AG Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
WO2004103279A2 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
ATE537825T1 (de) 2003-05-19 2012-01-15 Irm Llc Immunosuppressive verbindungen und zusammensetzungen
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2004113330A1 (en) 2003-05-19 2004-12-29 Irm Llc Immunosuppressant compounds and compositions
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
JP2005047899A (ja) 2003-07-11 2005-02-24 Sankyo Co Ltd アミノアルコール化合物
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
TW200510437A (en) 2003-08-12 2005-03-16 Mitsubishi Pharma Corp Phosphinane compound with immunomodulating activity
MXPA06002349A (es) 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
ES2754221T3 (es) 2003-08-29 2020-04-16 Ono Pharmaceutical Co Compuesto capaz de unirse al receptor de S1P y uso farmacéutico del mismo
US7825109B2 (en) * 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
EP1670463A2 (en) * 2003-10-01 2006-06-21 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
GB0324210D0 (en) * 2003-10-15 2003-11-19 Novartis Ag Organic compounds
US7638637B2 (en) * 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2005044780A1 (ja) 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
CN1894225A (zh) 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
TW200526548A (en) 2003-12-25 2005-08-16 Sankyo Co Ether derivatives
GB0401332D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005082841A1 (en) 2004-02-24 2005-09-09 Irm Llc Immunosuppressant compounds and compositions
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
CN1921847B (zh) 2004-02-24 2010-06-16 三共株式会社 氨基醇化合物
JP2005247691A (ja) 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
GB0405289D0 (en) * 2004-03-09 2004-04-21 Novartis Ag Organic compounds
GB0411929D0 (en) * 2004-05-27 2004-06-30 Novartis Ag Organic compounds
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
BRPI0514316A (pt) 2004-08-13 2008-06-10 Praecis Pharm Inc métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
PT2511262T (pt) * 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
US7888527B2 (en) 2004-12-06 2011-02-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
TW200702326A (en) 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
CA2820510A1 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases
BRPI0617077A2 (pt) 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
EP1935874A4 (en) 2005-10-12 2010-10-13 Toa Eiyo Ltd S1P3 RECEPTOR ANTAGONIST
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
TW200811083A (en) 2006-04-28 2008-03-01 Mitsubishi Pharma Corp 2-aminobutanol compounds and their medical use
CN101505744A (zh) * 2006-07-25 2009-08-12 爱尔康研究有限公司 用于预防和治疗眼部病症的内皮分化基因亚家庭3（edg-3，s1p3）受体的拮抗剂
US7877152B2 (en) * 2006-07-31 2011-01-25 JusJas LLC Bipolar stimulation/recording device with widely spaced electrodes

Also Published As

Publication number Publication date
CA2659599C (en) 2014-06-17
EP2053038A1 (en) 2009-04-29
EP2053038B1 (en) 2016-10-05
AU2007282556A1 (en) 2008-02-14
NZ574012A (en) 2012-02-24
AU2007282556B2 (en) 2012-03-08
JPWO2008018447A1 (ja) 2009-12-24
CN101506145A (zh) 2009-08-12
IL196274A0 (en) 2009-09-22
RU2458044C2 (ru) 2012-08-10
MX2009001457A (es) 2009-02-19
TWI396677B (zh) 2013-05-21
JP5140593B2 (ja) 2013-02-06
CO6160222A2 (es) 2010-05-20
EP2053038A4 (en) 2012-04-11
HK1131120A1 (en) 2010-01-15
IL196274A (en) 2013-12-31
ZA200900207B (en) 2009-12-30
TNSN08546A1 (en) 2010-04-14
GT200900024A (es) 2010-03-11
WO2008018447A1 (en) 2008-02-14
US20100010000A1 (en) 2010-01-14
MY146775A (en) 2012-09-28
US8273748B2 (en) 2012-09-25
KR20090041424A (ko) 2009-04-28
CN101506145B (zh) 2013-05-29
SG174029A1 (en) 2011-09-29
TW200815319A (en) 2008-04-01
MA30664B1 (fr) 2009-08-03
RU2009106935A (ru) 2010-09-20
CA2659599A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
LTC1729576I2 (lt) Fungicidinė kompozicija, apimanti piridiletilbenzamido darinį ir junginį, galintį slopinti ergosterolio biosintezę
NO20090202L (no) Prolylhydroksylaseinhibitorer
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
TW200638933A (en) Compounds for inflammation and immune-related uses
NO20073764L (no) Sammensetninger for behandling av HCV
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
NO20091704L (no) Inhibitorer av hepatitt C virus
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
NO20091707L (no) Inhibitorer av hepatitt C virus
NO20076648L (no) Novel thiophene derivatives
ATE433447T1 (de) Pyrimiidinverbindungen
NO20062099L (no) Synergistiske fungicide aktive substanskombinasjoner
NO20084583L (no) Makrosykliske kinase-inhibitorer
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20074739L (no) Amidderivater som ionkanalligander og farmasoytiske sammensetninger og fremgangsmater for anvendelse av samme
NO20072939L (no) Makroloner - aminosubstituerte kinoloner
NO20090619L (no) Aminoalkohol-derivatat og immunosuppressiv agent har det samme som en aktive ingrediens
EA200800817A1 (ru) Пестицидные производные бифениламидина
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
NZ608846A (en) Aryloxyurea compound and pest control agent
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
NO20064344L (no) Caspaseinhibitorer og anvendelser derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application